RecruitingNCT04398992

Additive Anti-inflammatory Action for Aortopathy & Arteriopathy

Chinese Registry of Additive Anti-inflammatory Action for Aortopathy & Arteriopathy (5A) Protocol: Rationale, Design and Methodology


Sponsor

Nanjing Medical University

Enrollment

10,000 participants

Start Date

Jan 1, 2016

Study Type

OBSERVATIONAL

Conditions

Summary

Acute aortic syndrome (AAS) is a life-threatening condition. Inflammation plays a key role in the pathogenesis, development and progression of AAS, and is associated with significant mortality and morbidity. Understanding the inflammatory responses and inflammation resolutions is essential for an appropriate management of AAS. Twenty Chinese cardiovascular centers have collaborated to create a multicenter observational registry (named Chinese registry of Additive Anti-inflammatory Action for Aortopathy \& Arteriopathy \[5A\]), with consecutive enrollment of adult patients who underwent surgery for AAS that was started on Jan 1, 2016 and will be ended on December 31, 2040. Specially, the impact of inflammation and anti-inflammatory strategies on the early and late adverse events are investigated. Primary outcomes are severe systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), Sequential Organ Failure Assessment (SOFA) scores at 7 days following this current surgery. Secondary outcomes are SISR, 30-day mortality, operative mortality, hospital mortality, new-onset stroke, acute kidney injury, surgical site infection, reoperation for bleeding, blood transfusion and length of stay in the intensive care unit.


Eligibility

Min Age: 18 Years

Inclusion Criteria5

  • Aged 18 years or older.
  • Patients with diagnosis of AAS, including aortic dissection, penetrating aortic ulcer or intramural hematoma.
  • Symptoms started within 14 days from surgery.
  • Patients received medical therapy, open surgical, endovascular, or hybrid repair.
  • Any other major cardiac surgical procedure concomitant with surgery for AAS, such as coronary artery bypass grafting or carotid artery replacement;

Exclusion Criteria4

  • Patients aged < 18 years.
  • Onset of symptoms > 14 days from surgery.
  • AAS secondary to traumatic or iatrogenic injury.
  • Patients who declined participation in registration and follow-up investigation.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERobservation

Data were collected by a designed form. Statistic software was used to analyze clinical data.


Locations(34)

Beijing Fuwai Hospital Chinese Academy of Medical Sciences

Beijing, Beijing Municipality, China

Chongqing Hospital of Jiangsu Provincial People's Hospital

Chongqing, Chongqing Municipality, China

Guangdong Provincial People's Hospital

Guangzhou, Guangdong, China

The First Affiliated Hospital of Guangxi Medical University

Nanning, Guangxi, China

QianXiNan People's Hospital

Xingyi, Guizhou, China

The Second Affiliated Hospital of Harbin Medical University

Harbin, Heilongjiang, China

The Third Affiliated Hospital of Soochow University

Changzhou, Jiangsu, China

Suqian Hospital of of Nanjing Medical University

Suqian, Jiangsu, China

Dongtai People's Hospital

Yancheng, Jiangsu, China

Subei People's Hospital of Jiangsu Province

Yangzhou, Jiangsu, China

the Second Affiliated Hospital of Nanchang University

Nanchang, Jiangxi, China

Qilu Hospital of Shandong University

Jinan, Shandong, China

Shanghai DeltaHealth Hospital

Shanghai, Shanghai Municipality, China

Shanxi Cardiovascular Hospital

Taiyuan, Shanxi, China

West China Hospital of Sichuan University

Chengdu, Sichuan, China

The Seventh Affiliated Hospital of Xinjiang Medical University

Ürümqi, Xinjiang, China

The Friendship Hospital of Yili Kazak Autonomous Prefecture

Yining, Xinjiang, China

The First Affiliated Hospital of Kunming Medical University

Kunming, Yunnan, China

Zhejiang Provincial People's Hospital

Hangzhou, Zhejiang, China

The First Affiliated Hospital of Wenzhou Medical University

Wenzhou, Zhejiang, China

Beijing Anzhen Hospital Capital Medical University

Beijing, China

Beijing Chaoyang Hospital

Beijing, China

the First Affiliated Hospital of Bengbu Medical College

Bengbu, China

Xiangya Hospital Central South University

Changsha, China

The First Affiliated Hospital of Guangzhou Medical University

Guangzhou, China

the First Affiliated Hospital of Guilin Medical College

Guilin, China

The First Affiliated Hospital of Nanjing Medical University

Nanjing, China

Nanjing First Hospital, Nanjing Medical University

Nanjing, China

the Affiliated Hospital of Qingdao University

Qingdao, China

Shanghai East Hospital Tongji University

Shanghai, China

the First Affiliated Hospital of Shantou University Medical College

Shantou, China

Teda International Cardiovascular Hospital

Tianjin, China

Tianjin Chest Hospital

Tianjin, China

Xiamen Cardiovascular Hospital

Xiamen, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04398992


Related Trials